Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-3 ICO vs IV Injection in Acute Large Hemispheric Infarction
NCT06374667Recruiting
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of loberamisal in brain infarction (2 arms). Primary endpoint: Modified Rankin Scale 0-3 at 90 days. Started Apr 2024; status: recruiting.
02
Drugs
loberamisal
03
Conditions
brain infarction
Beyond the preview
Go deeper on NCT06374667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374667.